These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37794723)

  • 1. Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review.
    Arsenault-Mehta K; Hochman-Bérard M; Johnson A; Semenova D; Nguyen B; Willis J; Mouravska N; Joober R; Zhand N
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):2-16. PubMed ID: 37794723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modafinil for people with schizophrenia or related disorders.
    Ortiz-Orendain J; Covarrubias-Castillo SA; Vazquez-Alvarez AO; Castiello-de Obeso S; Arias Quiñones GE; Seegers M; Colunga-Lozano LE
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008661. PubMed ID: 31828767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cognitive remediation and cognitive assistive technologies in schizophrenia].
    Sablier J; Stip E; Franck N
    Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
    Kirkman MA; Day J; Gehring K; Zienius K; Grosshans D; Taphoorn M; Li J; Brown PD
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD011335. PubMed ID: 36427235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Learning potential and cognitive remediation in schizophrenia].
    Raffard S; Gely-Nargeot MC; Capdevielle D; Bayard S; Boulenger JP
    Encephale; 2009 Sep; 35(4):353-60. PubMed ID: 19748372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
    Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
    J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages.
    Mayeli A; Clancy KJ; Sonnenschein S; Sarpal DK; Ferrarelli F
    Psychiatry Res; 2022 Nov; 317():114926. PubMed ID: 36932470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique.
    Allott K; Liu P; Proffitt TM; Killackey E
    Schizophr Res; 2011 Feb; 125(2-3):221-35. PubMed ID: 21111577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neurocognitive insight in schizophrenia: a meta-analysis].
    Potvin S; Pelletier J; Stip E
    Sante Ment Que; 2014; 39(2):183-200. PubMed ID: 25590551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive training for people with mild to moderate dementia.
    Bahar-Fuchs A; Martyr A; Goh AM; Sabates J; Clare L
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD013069. PubMed ID: 30909318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidant treatments for schizophrenia.
    Magalhães PV; Dean O; Andreazza AC; Berk M; Kapczinski F
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008919. PubMed ID: 26848926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
    Keefe RS; Silva SG; Perkins DO; Lieberman JA
    Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient outcomes in schizophrenia II: the impact of cognition.
    Hofer A; Baumgartner S; Bodner T; Edlinger M; Hummer M; Kemmler G; Rettenbacher MA; Fleischhacker WW
    Eur Psychiatry; 2005 Aug; 20(5-6):395-402. PubMed ID: 16171654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics and impact of metacognitive deficits in schizophrenia].
    Quiles C; Prouteau A; Verdoux H
    Encephale; 2013 Apr; 39(2):123-9. PubMed ID: 23219408
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.